Weller, J. 
; Schäfer, N. ; Schaub, C. ; Tzaridis, T. ; Zeyen, T. ; Schneider, M. ; Potthoff, A. L. ; Giordano, F. A. ; Steinbach, J. P. ; Zeiner, P. S. ; Kowalski, T. ; Sabel, M. ; Hau, P. ; Krex, D. ; Grauer, O. ; Goldbrunner, R. ; Schnell, O. ; Tabatabai, G. ; Ringel, F. ; Schmidt-Graf, F. ; Brehmer, S. ; Tonn, J. C. ; Bullinger, L. ; Vajkoczy, P. ; Glas, M. ; Vatter, H. ; Herrlinger, U. ; Seidel, C.
; Schäfer, N. ; Schaub, C. ; Tzaridis, T. ; Zeyen, T. ; Schneider, M. ; Potthoff, A. L. ; Giordano, F. A. ; Steinbach, J. P. ; Zeiner, P. S. ; Kowalski, T. ; Sabel, M. ; Hau, P. ; Krex, D. ; Grauer, O. ; Goldbrunner, R. ; Schnell, O. ; Tabatabai, G. ; Ringel, F. ; Schmidt-Graf, F. ; Brehmer, S. ; Tonn, J. C. ; Bullinger, L. ; Vajkoczy, P. ; Glas, M. ; Vatter, H. ; Herrlinger, U. ; Seidel, C. 
Abstract
Purpose In the randomized phase III trial CeTeG/NOA-09, temozolomide (TMZ)/lomustine (CCNU) combination therapy was superior to TMZ in newly diagnosed MGMT methylated glioblastoma, albeit reporting more frequent hematotoxicity. Here, we analyze high grade hematotoxicity and its prognostic relevance in the trial population.Methods Descriptive and comparative analysis of hematotoxicity adverse ...
Owner only: item control page
Altmetric